118 related articles for article (PubMed ID: 37536559)
1. Effect of CDK7 inhibitor on MYCN-amplified retinoblastoma.
Xu H; Xiao L; Chen Y; Liu Y; Zhang Y; Gao Y; Man S; Yan N; Zhang M
Biochim Biophys Acta Gene Regul Mech; 2023 Sep; 1866(3):194964. PubMed ID: 37536559
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma.
Tee AE; Ciampa OC; Wong M; Fletcher JI; Kamili A; Chen J; Ho N; Sun Y; Carter DR; Cheung BB; Marshall GM; Liu PY; Liu T
Int J Cancer; 2020 Oct; 147(7):1928-1938. PubMed ID: 32086952
[TBL] [Abstract][Full Text] [Related]
3. Silencing of the Long Noncoding RNA MYCNOS1 Suppresses Activity of MYCN-Amplified Retinoblastoma Without RB1 Mutation.
Saengwimol D; Chittavanich P; Laosillapacharoen N; Srimongkol A; Chaitankar V; Rojanaporn D; Aroonroch R; Suktitipat B; Saisawang C; Svasti S; Hongeng S; Kaewkhaw R
Invest Ophthalmol Vis Sci; 2020 Dec; 61(14):8. PubMed ID: 33270844
[TBL] [Abstract][Full Text] [Related]
4. CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer.
Wang J; Zhang R; Lin Z; Zhang S; Chen Y; Tang J; Hong J; Zhou X; Zong Y; Xu Y; Meng R; Xu S; Liu L; Zhang T; Yang K; Dong X; Wu G
J Hematol Oncol; 2020 Jul; 13(1):99. PubMed ID: 32690037
[TBL] [Abstract][Full Text] [Related]
5. CDK7 blockade suppresses super-enhancer-associated oncogenes in bladder cancer.
Yang Y; Jiang D; Zhou Z; Xiong H; Yang X; Peng G; Xia W; Wang S; Lei H; Zhao J; Qian Z; Wu S; Pang J
Cell Oncol (Dordr); 2021 Aug; 44(4):871-887. PubMed ID: 33905040
[TBL] [Abstract][Full Text] [Related]
6. Ceftriaxone exerts antitumor effects in MYCN-driven retinoblastoma and neuroblastoma by targeting DDX3X for translation repression.
Chittavanich P; Saengwimol D; Roytrakul S; Rojanaporn D; Chaitankar V; Srimongkol A; Anurathapan U; Hongeng S; Kaewkhaw R
Mol Oncol; 2024 Apr; 18(4):918-938. PubMed ID: 37975412
[TBL] [Abstract][Full Text] [Related]
7.
De Rosa P; Severi F; Zadran SK; Russo M; Aloisi S; Rigamonti A; Capranico G; Milazzo G; Perini G
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982482
[TBL] [Abstract][Full Text] [Related]
8. THZ1 targeting CDK7 suppresses c-KIT transcriptional activity in gastrointestinal stromal tumours.
Sun J; Zhang Q; Sun X; Xue A; Gao X; Shen K
Cell Commun Signal; 2022 Sep; 20(1):138. PubMed ID: 36076237
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylation of pRb: mechanism for RB pathway inactivation in MYCN-amplified retinoblastoma.
Ewens KG; Bhatti TR; Moran KA; Richards-Yutz J; Shields CL; Eagle RC; Ganguly A
Cancer Med; 2017 Mar; 6(3):619-630. PubMed ID: 28211617
[TBL] [Abstract][Full Text] [Related]
10. CDK7 inhibitor THZ1 inhibits MCL1 synthesis and drives cholangiocarcinoma apoptosis in combination with BCL2/BCL-XL inhibitor ABT-263.
Huang T; Ding X; Xu G; Chen G; Cao Y; Peng C; Shen S; Lv Y; Wang L; Zou X
Cell Death Dis; 2019 Aug; 10(8):602. PubMed ID: 31399555
[TBL] [Abstract][Full Text] [Related]
11.
Price EA; Patel R; Scheimberg I; Kotiloglu Karaa E; Sagoo MS; Reddy MA; Onadim Z
Ophthalmic Genet; 2021 Oct; 42(5):604-611. PubMed ID: 34003079
[No Abstract] [Full Text] [Related]
12. Targeting Super-Enhancer-Driven Oncogenic Transcription by CDK7 Inhibition in Anaplastic Thyroid Carcinoma.
Cao X; Dang L; Zheng X; Lu Y; Lu Y; Ji R; Zhang T; Ruan X; Zhi J; Hou X; Yi X; Li MJ; Gu T; Gao M; Zhang L; Chen Y
Thyroid; 2019 Jun; 29(6):809-823. PubMed ID: 30924726
[No Abstract] [Full Text] [Related]
13. Nanomaterial-Facilitated Cyclin-Dependent Kinase 7 Inhibition Suppresses Gallbladder Cancer Progression via Targeting Transcriptional Addiction.
Huang CS; Xu QC; Dai C; Wang L; Tien YC; Li F; Su Q; Huang XT; Wu J; Zhao W; Yin XY
ACS Nano; 2021 Sep; 15(9):14744-14755. PubMed ID: 34405985
[TBL] [Abstract][Full Text] [Related]
14. The Covalent CDK7 Inhibitor THZ1 Potently Induces Apoptosis in Multiple Myeloma Cells
Zhang Y; Zhou L; Bandyopadhyay D; Sharma K; Allen AJ; Kmieciak M; Grant S
Clin Cancer Res; 2019 Oct; 25(20):6195-6205. PubMed ID: 31358538
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of high level E2F in a RB1 proficient MYCN overexpressing chicken retinoblastoma model normalizes neoplastic behaviour.
Zhang H; Konjusha D; Rafati N; Tararuk T; Hallböök F
Cell Oncol (Dordr); 2024 Feb; 47(1):209-227. PubMed ID: 37606819
[TBL] [Abstract][Full Text] [Related]
16. Suppression of Angiogenesis by Targeting Cyclin-Dependent Kinase 7 in Human Umbilical Vein Endothelial Cells and Renal Cell Carcinoma: An In Vitro and In Vivo Study.
Shi CS; Kuo KL; Chen MS; Chow PM; Liu SH; Chang YW; Lin WC; Liao SM; Hsu CH; Hsu FS; Chang HC; Huang KH
Cells; 2019 Nov; 8(11):. PubMed ID: 31752390
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological inhibition of CDK7 by THZ1 impairs tumor growth in p53-mutated HNSCC.
Ge H; Yao Y; Jiang Y; Wu X; Wang Y
Oral Dis; 2022 Apr; 28(3):611-620. PubMed ID: 33503275
[TBL] [Abstract][Full Text] [Related]
18. CDK7 inhibition as a promising therapeutic strategy for lung squamous cell carcinomas with a SOX2 amplification.
Hur JY; Kim HR; Lee JY; Park S; Hwang JA; Kim WS; Yoon S; Choi CM; Rho JK; Lee JC
Cell Oncol (Dordr); 2019 Aug; 42(4):449-458. PubMed ID: 30838525
[TBL] [Abstract][Full Text] [Related]
19. CDK7 Inhibition is Effective in all the Subtypes of Breast Cancer: Determinants of Response and Synergy with EGFR Inhibition.
McDermott MSJ; Sharko AC; Munie J; Kassler S; Melendez T; Lim CU; Broude EV
Cells; 2020 Mar; 9(3):. PubMed ID: 32155786
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive characterization of RB1 mutant and MYCN amplified retinoblastoma cell lines.
Schwermer M; Hiber M; Dreesmann S; Rieb A; Theißen J; Herold T; Schramm A; Temming P; Steenpass L
Exp Cell Res; 2019 Feb; 375(2):92-99. PubMed ID: 30584916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]